Acorda Therapeutics Inc Revenue Growth Rates (ACORQ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Acorda Therapeutics Inc   (ACORQ)
 

ACORQ's Revenue Growth by Quarter and Year

Acorda Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACORQ Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 20.29
FY 20.29

ACORQs Annual Revenue
Acorda Therapeutics Inc 's Revenue in the fiscal year 2023 $ 117.63 millions
Acorda Therapeutics Inc 's Revenue in the fiscal year 2022 $ 118.57 millions
Acorda Therapeutics Inc 's Revenue in the fiscal year 2021 $ 129.07 millions
Acorda Therapeutics Inc 's Revenue in the fiscal year 2020 $ 152.97 millions
Acorda Therapeutics Inc 's Revenue in the fiscal year 2019 $ 192.41 millions




ACORQ Revenue first quarter 2024 Y/Y Growth Comment
Acorda Therapeutics Inc reported decrease in Revenue in the first quarter 2024 by -8.85% to $ 20.29 millions, from the same quarter in 2023.
The decrease in the first quarter 2024 Acorda Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 14.03%.

Looking into first quarter 2024 results within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue growth. While Acorda Therapeutics Inc ' s Revenue decline of -8.85% ranks overall at the positon no. 3063 in the first quarter 2024.


ACORQ Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 20.72 % -14.88 % -3.12 %
3rd Quarter September - -17.28 % 6.52 % -40.74 %
2nd Quarter June - -4.41 % -2.33 % -5.44 %
1st Quarter March -8.85 % -1.2 % -21.93 % 2.7 %
FY   - -0.77 % -8.15 % -

Financial Statements
Acorda Therapeutics Inc 's first quarter 2024 Revenue $ 20.29 millions ACORQ's Income Statement
Acorda Therapeutics Inc 's first quarter 2023 Revenue $ 22.26 millions Quarterly ACORQ's Income Statement


ACORQ Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 37.05 % -6.09 % 17.51 %
3rd Quarter September - -6.6 % 7.92 % -1.04 %
2nd Quarter June - 33.33 % 37.82 % 10.15 %
1st Quarter March -46.59 % -29.27 % -39.06 % -24.37 %
FY (Year on Year)   - -0.77 % -8.15 % -


Back to ACORQ Growth rate Comparisons >> Back to ACORQ Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #463
Overall #3063

Revenue Y/Y Growth Statistics
High Average Low
318.17 % 14.03 % -67.35 %
(Sep. 30, 2015)   (Sep 30 2019)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #463
Overall #3063
Revenue Y/Y Growth Statistics
High Average Low
318.17 % 14.03 % -67.35 %
(Sep. 30, 2015)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Acorda Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
57.92 % 0.98 % -45.77 %
(Sep 30 2020)  


ACORQ's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Acorda Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -46.59% to $ 20.29 millions, from $ 37.99 millions achived in the previous reporting period.

But that's not important problem, as Acorda Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Acorda Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3166.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #448
Overall #3166
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #448
Overall #3166
Revenue Q/Q Growth Statistics
High Average Low
57.92 % 0.98 % -45.77 %
(Sep 30 2020)  


ACORQ's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Acorda Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -46.59% to $ 20.29 millions, from $ 37.99 millions achived in the previous reporting period.

But that's not important problem, as Acorda Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Acorda Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3166.


Acorda Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 115.66 $ 117.63 $ 111.12 $ 116.91 $ 118.29
Y / Y Revenue Growth (TTM) -2.22 % -0.79 % -10.43 % -4.18 % -3.63 %
Year on Year Revenue Growth Overall Ranking # 2340 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -1.67 % 5.86 % -4.96 % -1.16 % -0.23 %
Seq. Revenue Growth (TTM) Overall Ranking # 1774 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Acorda Therapeutics Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.22% year on year, at Mar 31 2024 compare to the -0.79% decrease at Dec 31 2023. If the Acorda Therapeutics Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $116 millions.

In the Healthcare sector 368 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2340.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 369
Overall # 2340

Revenue TTM Y/Y Growth Statistics
High Average Low
27.49 %
 -5.49 %
-62.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 314
S&P 500 # 1774
Cumulative Revenue growth Comment
Acorda Therapeutics Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.22% year on year, at Mar 31 2024 compare to the -0.79% decrease at Dec 31 2023. If the Acorda Therapeutics Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $116 millions.

In the Healthcare sector 368 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2340.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 369
Overall # 2340

Revenue TTM Y/Y Growth Statistics
High Average Low
27.49 %
-5.49 %
-62.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 314
S&P 500 # 1774




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACORQ's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical Inc -0.21%$ -0.215 millions
Mettler toledo International Inc -0.30%$ -0.300 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
3m Company-0.64%$ -0.644 millions
Orgenesis Inc -0.70%$ -0.704 millions
T2 Biosystems Inc -0.82%$ -0.818 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Enhabit Inc -1.02%$ -1.018 millions
Valneva Se-1.11%$ -1.112 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Zimvie Inc -1.84%$ -1.836 millions
Sight Sciences Inc -1.87%$ -1.870 millions
Opus Genetics Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Wave Life Sciences Ltd -3.02%$ -3.024 millions
Fulgent Genetics Inc -3.12%$ -3.119 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions


About Acorda Therapeutics Inc Revenue Growth Rates (ACORQ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Acorda Therapeutics Inc (CIK 1008848).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-059114
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Acorda Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.